Delaware
|
000-50644
|
77-0492262
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
|
Description
|
|
Press Release of Cutera, Inc. dated as of May 6, 2013.
|
CUTERA, INC.
|
|
Date: May 6, 2013
|
/s/ KEVIN P. CONNORS
|
Kevin P. Connors
|
|
President and Chief Executive Officer
|
|
·
|
Revenue grew 2% to $16.0 million, compared to the first quarter of 2012 in what is historically the seasonally lowest quarter of the year.
|
|
·
|
Gross margin was 54%, compared to the 50% in the first quarter of 2012, due primarily to the elimination of non-recurring acquisition start-up expenses associated with the Iridex asset purchase that were included in the first quarter of 2012.
|
|
·
|
Net loss was $2.2 million, or $0.15 per diluted share. Stock-based compensation, intangible, and depreciable items totaled $1.1 million for the quarter.
|
|
·
|
Cash and marketable securities increased $2.5 million in the quarter, resulting in $88.1 million at the end of the quarter.
|
|
1)
|
Launching a new disposable applicator for the truSculpt system to treat the smaller cosmetic areas of the body. truSculpt has the commercial advantage of being a platform where we are able to launch new applicators to better treat different parts of the body, as well as the potential to pursue other aesthetic applications.
|
|
2)
|
Introducing a new high performance laser system that is planned to be launched near the end of the year. More details on this project will be forthcoming with the release of our second quarter 2013 results.
|
|
3)
|
Our Picosecond research program for the tattoo and pigmented lesion removal market continues to make progress. We have built a working prototype, have started conducting clinical trials, and are now in the process of working on a 510(k) submission for this product. We recently met with the FDA to discuss our regulatory path and are encouraged with the direction from the Agency.”
|
March 31,
|
December 31,
|
March 31,
|
||||||||||
2013
|
2012
|
2012
|
||||||||||
Assets
|
||||||||||||
Current assets:
|
||||||||||||
Cash and cash equivalents
|
$ | 17,272 | $ | 23,546 | $ | 12,787 | ||||||
Marketable investments
|
70,821 | 62,026 | 66,137 | |||||||||
Accounts receivable, net
|
6,814 | 8,841 | 4,496 | |||||||||
Inventories
|
11,091 | 11,114 | 13,434 | |||||||||
Deferred tax asset
|
39 | 40 | 50 | |||||||||
Other current assets and prepaid expenses
|
1,511 | 1,439 | 1,363 | |||||||||
Total current assets
|
107,548 | 107,006 | 98,267 | |||||||||
Property and equipment, net
|
1,312 | 933 | 1,019 | |||||||||
Long-term investments
|
- | - | 2,928 | |||||||||
Deferred tax asset, net of current portion
|
518 | 553 | 450 | |||||||||
Intangibles, net
|
2,392 | 2,566 | 3,504 | |||||||||
Goodwill
|
1,339 | 1,339 | 1,339 | |||||||||
Other long-term assets
|
362 | 397 | 458 | |||||||||
Total assets
|
$ | 113,471 | $ | 112,794 | $ | 107,965 | ||||||
Liabilities and Stockholders' Equity
|
||||||||||||
Current liabilities:
|
||||||||||||
Accounts payable
|
$ | 2,161 | $ | 2,107 | $ | 2,674 | ||||||
Accrued liabilities
|
7,087 | 9,493 | 8,936 | |||||||||
Deferred revenue
|
6,766 | 6,618 | 5,770 | |||||||||
Total current liabilities
|
16,014 | 18,218 | 17,380 | |||||||||
Deferred revenue, net of current portion
|
2,538 | 2,102 | 917 | |||||||||
Income tax liability
|
320 | 412 | 469 | |||||||||
Other long-term liabilities
|
1,449 | 1,288 | 1,450 | |||||||||
Total liabilities
|
20,321 | 22,020 | 20,216 | |||||||||
Stockholders’ equity:
|
||||||||||||
Common stock
|
14 | 14 | 14 | |||||||||
Additional paid-in capital
|
105,089 | 100,552 | 97,043 | |||||||||
Accumulated deficit
|
(12,036 | ) | (9,873 | ) | (8,592 | ) | ||||||
Accumulated other comprehensive income (loss)
|
83 | 81 | (716 | ) | ||||||||
Total stockholders' equity
|
93,150 | 90,774 | 87,749 | |||||||||
Total liabilities and stockholders' equity
|
$ | 113,471 | $ | 112,794 | $ | 107,965 |
Three Months Ended
|
||||||||||||
March 31,
|
December 31,
|
March 31,
|
||||||||||
2013
|
2012
|
2012
|
||||||||||
Net revenue
|
$ | 15,967 | $ | 22,533 | $ | 15,727 | ||||||
Cost of revenue
|
7,417 | 9,790 | 7,845 | |||||||||
Gross profit
|
8,550 | 12,743 | 7,882 | |||||||||
Operating expenses:
|
||||||||||||
Sales and marketing
|
6,456 | 7,101 | 7,437 | |||||||||
Research and development
|
2,121 | 2,122 | 2,216 | |||||||||
General and administrative
|
2,289 | 2,452 | 3,495 | |||||||||
Total operating expenses
|
10,866 | 11,675 | 13,148 | |||||||||
Income (loss) from operations
|
(2,316 | ) | 1,068 | (5,266 | ) | |||||||
Interest and other income, net
|
135 | 105 | 96 | |||||||||
Income (loss) before income taxes
|
(2,181 | ) | 1,173 | (5,170 | ) | |||||||
Provision (benefit) for income taxes
|
(18 | ) | 96 | 97 | ||||||||
Net income (loss)
|
$ | (2,163 | ) | $ | 1,077 | $ | (5,267 | ) | ||||
Net income (loss) per share:
|
||||||||||||
Basic
|
$ | (0.15 | ) | $ | 0.08 | $ | (0.38 | ) | ||||
Diluted
|
$ | (0.15 | ) | $ | 0.08 | $ | (0.38 | ) | ||||
Weighted-average number of shares used in per share calculations:
|
||||||||||||
Basic
|
14,408 | 14,173 | 13,960 | |||||||||
Diluted
|
14,408 | 14,272 | 13,960 |
Three Months Ended
|
||||||||||||
March 31,
|
December 31,
|
March 31,
|
||||||||||
2013
|
2012
|
2012
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Net income (loss)
|
$ | (2,163 | ) | $ | 1,077 | $ | (5,267 | ) | ||||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
Stock-based compensation
|
820 | 826 | 738 | |||||||||
Tax benefit from stock-based compensation
|
- | 6 | - | |||||||||
Excess tax benefit related to stock-based compensation
|
- | (6 | ) | - | ||||||||
Depreciation and amortization
|
320 | 420 | 343 | |||||||||
Other
|
34 | 26 | 14 | |||||||||
Changes in assets and liabilities:
|
||||||||||||
Accounts receivable
|
2,027 | (992 | ) | 640 | ||||||||
Inventories
|
23 | 1,363 | (1,153 | ) | ||||||||
Other current assets and prepaid expenses
|
60 | 142 | 444 | |||||||||
Other long-term assets
|
35 | 120 | 28 | |||||||||
Accounts payable
|
54 | (190 | ) | 101 | ||||||||
Accrued liabilities
|
(2,504 | ) | (14 | ) | (661 | ) | ||||||
Other long-term liabilities
|
259 | (38 | ) | 27 | ||||||||
Deferred revenue
|
584 | 1,010 | (118 | ) | ||||||||
Income tax liability
|
(92 | ) | (59 | ) | (9 | ) | ||||||
Net cash provided by (used in) operating activities
|
(543 | ) | 3,691 | (4,873 | ) | |||||||
Cash flows from investing activities:
|
||||||||||||
Acquisition of property and equipment
|
(525 | ) | (158 | ) | (277 | ) | ||||||
Business acquisition
|
- | - | (5,091 | ) | ||||||||
Proceeds from sales of marketable and long-term investments
|
500 | 5,203 | 10,729 | |||||||||
Proceeds from maturities of marketable investments
|
11,050 | 8,564 | 11,135 | |||||||||
Purchase of marketable investments
|
(20,473 | ) | (18,949 | ) | (13,442 | ) | ||||||
Net cash provided by (used in) investing activities
|
(9,448 | ) | (5,340 | ) | 3,054 | |||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from exercise of stock options and employee stock purchase plan
|
3,717 | 855 | 586 | |||||||||
Excess tax benefit related to stock-based compensation
|
- | 6 | - | |||||||||
Net cash provided by financing activities
|
3,717 | 861 | 586 | |||||||||
Net decrease in cash and cash equivalents
|
(6,274 | ) | (788 | ) | (1,233 | ) | ||||||
Cash and cash equivalents at beginning of period
|
23,546 | 24,334 | 14,020 | |||||||||
Cash and cash equivalents at end of period
|
$ | 17,272 | $ | 23,546 | $ | 12,787 |
Three Months Ended
|
||||||||||||||||||||||||
March 31,
|
% of
|
December 31,
|
% of
|
March 31,
|
% of
|
|||||||||||||||||||
2013
|
Revenue
|
2012
|
Revenue
|
2012
|
Revenue
|
|||||||||||||||||||
Revenue By Geography:
|
||||||||||||||||||||||||
United States
|
$ | 6,488 | 41 | % | $ | 10,008 | 44 | % | $ | 6,311 | 40 | % | ||||||||||||
International
|
9,479 | 59 | % | 12,525 | 56 | % | 9,416 | 60 | % | |||||||||||||||
$ | 15,967 | $ | 22,533 | $ | 15,727 | |||||||||||||||||||
Revenue By Product Category:
|
||||||||||||||||||||||||
Products and upgrades
|
$ | 9,197 | 58 | % | $ | 15,326 | 68 | % | $ | 9,258 | 59 | % | ||||||||||||
Service
|
4,444 | 28 | % | 4,614 | 20 | % | 3,873 | 25 | % | |||||||||||||||
Titan and truSculpt hand piece refills
|
1,190 | 7 | % | 1,235 | 6 | % | 1,130 | 7 | % | |||||||||||||||
Dermal fillers and cosmeceuticals
|
1,136 | 7 | % | 1,358 | 6 | % | 1,466 | 9 | % | |||||||||||||||
$ | 15,967 | $ | 22,533 | $ | 15,727 |
Three Months Ended
|
||||||||||||
March 31,
|
|
December 31,
|
|
March 31,
|
||||||||
2013
|
2012
|
2012
|
||||||||||
Pre-tax Stock-Based Compensation Expense:
|
||||||||||||
Cost of revenue
|
$
|
159
|
$
|
178
|
$
|
143
|
||||||
Sales and marketing
|
199
|
181
|
140
|
|||||||||
Research and development
|
101
|
95
|
146
|
|||||||||
General and administrative
|
361
|
372
|
309
|
|||||||||
$
|
820
|
$
|
826
|
$
|
738
|